PMEF
ARCT icon

Point72 Middle East FZE’s Arcturus Therapeutics ARCT Stock Holding History

Point72 Middle East FZE’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-19,838
Closed -$569K – 1434
2023
Q2 		$569K Buy
19,838
+18,439
+1,318% +$502K 0.02% 742
2023
Q1 		$33.5K Sell
1,399
-3,274
-70% -$58.7K ﹤0.01% 1342
2022
Q4 		$79.3K Buy
+4,673
New +$81.5K ﹤0.01% 1347

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Middle East FZE's ARCT Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Arcturus Therapeutics (ARCT) in Q3 2023, closing a stake of 19,838 shares — an estimated $569K sold.

Point72 Middle East FZE first reported a position in ARCT in Q4 2022 and held it in 3 quarters. The position peaked at $569K in Q2 2023. 145 funds tracked by Wall St. Rank hold ARCT as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Arcturus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 19,838 Arcturus Therapeutics shares in Q3 2023, an estimated $569K.
  • Point72 Middle East FZE first reported a position in Arcturus Therapeutics in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Arcturus Therapeutics position peaked at $569K in Q2 2023.
  • 145 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.